Invion Stock

Invion EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Invion (IVX.AX) as of Jul 15, 2026 is -0.86. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.29 — a change of -33.59% (higher).

EV/EBIT

-0.86

YoY

-33.59%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Invion is 2026 -0.86 . EV/EBIT (Enterprise Value to EBIT) of Invion was 2025 -1.29 . It decreases by -33.59% higher compared to the previous year.

The Invion EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
-8,489.76 base
Jan 1, 2019
-2,837.88 base
Jan 1, 2020
-5,358.60 base
Jan 1, 2021
-7,380.97 base
Jan 1, 2022
-23.72 base
Jan 1, 2023
-19.88 base
Jan 1, 2024
-3.34 base
Jan 1, 2025
-0.83 base
YEARPRICE-TO-EBIT
2025 -0.83
2024 -3.34
2023 -19.88
2022 -23.72
2021 -7,380.97
2020 -5,358.60
2019 -2,837.88
2018 -8,489.76
2017 -394.11
2016 -58.53
2015 -29.43
2014 -337.90
2013 -634.03
2012 -297.16
2011 -73.81
2010 -121.44
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

Invion Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Invion's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Invion's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Invion's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Invion grows earnings faster than its peers.

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

EV/EBIT (Enterprise Value to EBIT) of Invion is -0.86 in 2026.

Access this data via the Eulerpool API

Valuation — Invion

All Key Metrics — Invion